Webinar
Cancer Is Losing: Why AI is changing the oncology investment case
Join Luca Giani, Senior Principal at Alumni Ventures, and Mike Collins, CEO and Founder of Alumni Ventures, as they examine how AI is reshaping oncology — and why this accelerating shift is changing the investment case for cancer innovation
Luca and Mike will explore how AI is transforming the oncology landscape and creating new possibilities across cancer research, diagnosis, treatment, and care. They will discuss why the convergence of artificial intelligence and life sciences could accelerate progress against cancer, reshape traditional development models, and create compelling opportunities for venture investors.
Whether you’re an experienced healthcare investor or exploring the intersection of AI and oncology for the first time, this session will provide a clear perspective on the technologies and market forces driving change. Register to understand why the oncology investment landscape is evolving — and where durable value may emerge as AI moves deeper into healthcare.
Want to access our Health Tech Fund startup deals to see, evaluate, and optionally invest? No cost, no commitment.
Why Attend?
- HomeDiscover how AI is changing the pace and possibilities of oncology innovation
- HomeUnderstand the forces reshaping how cancer-focused companies are developed and evaluated
- HomeExplore what this transformation could mean for investors seeking exposure to healthcare innovation
Rated a Top 20 VC Firm by both TIME and CB Insights.
Alumni Ventures is America’s largest venture capital firm for individual investors.
About your presenters
Senior Principal
Luca Giani is a Senior Principal, investor, and serial entrepreneur with a track record across venture creation, M&A, and translational science. He specializes in bridging science, strategy, capital, and talent to help build mission-driven ventures.
Luca was the Founder & CEO of Ilios Therapeutics, a neuroscience company developing a novel chemistry platform to address ALS, Parkinson’s, and Alzheimer’s disease. Under his leadership, Ilios built a diversified preclinical pipeline, advanced lead optimization, filed foundational IP, and positioned the company for strategic partnerships.
Luca is a Termeer Fellow, part of a global network of emerging biotech CEOs mentored by industry leaders. He previously served as a Blavatnik Fellow in Life Science Entrepreneurship at Harvard Business School, and as a Technology and Public Purpose Fellow at Harvard’s Belfer Center, appointed by and working with former U.S. Secretary of Defense Ash Carter, where he authored policy work on accelerating treatments for neurodegenerative diseases under the mentorship of Dr. Robert Langer.
Earlier in his career, Luca co-founded Innbiotec Pharma; led international investments in MedTech and digital health at 5Lion Ventures; and co-founded and commercialized Somnifix, a patented sleep apnea and snoring therapy. He began his career in M&A at Credit Suisse, followed by strategy consulting at Bain & Company in London, advising clients on market expansion, transformation, and operational optimization.
Luca holds a Master with Distinction from Harvard, has completed programs at Harvard Medical School, Harvard Business School, and MIT Sloan, and earned his B.S. magna cum laude from Georgetown University.
Mike has been involved in almost every facet of venturing, from angel investing to venture capital, new business and product launches, and innovation consulting. He is the CEO of Alumni Ventures and launched AV’s first alumni fund, Green D Ventures, where he oversaw the portfolio as Managing Partner and is now Managing Partner Emeritus. Mike is a serial entrepreneur who has started multiple companies, including Kid Galaxy, Big Idea Group (partially owned by WPP), and RDM. He began his career at VC firm TA Associates. He holds an undergraduate degree in Engineering Science from Dartmouth and an MBA from Harvard Business School.